What question did this study set out to answer?

The study aims to assess the immune-modulating effects of Lu-PSMA-617 radioligand therapy in prostate cancer.

¹⁷⁷lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates immune modulation in prostate cancer with Lu-PSMA-617, suggesting new treatment strategies.

The study aims to assess the immune-modulating effects of Lu-PSMA-617 radioligand therapy in prostate cancer.
Evaluated the effects of Lu-PSMA-617 on immune cell populations and tumor microenvironment factors.
Examined alternative radioligands like alpha-emitters in relation to immune modulation.
Identified the importance of biomarker-driven patient selection and combination strategies.
Lu-PSMA-617 therapy influences immune cell populations and induces immunogenic cell death.
Immunomodulatory potential is affected by tumor heterogeneity and microenvironmental factors.
Clinical impact can be optimized through tailored dosimetry and combination with immunotherapies.

Sciortino et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark